Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Pediatric Patients With Familial Chylomicronemia Syndrome (FCS)

NCT07727538 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07727538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07727538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Pediatric Patients With Familial Chylomicronemia Syndrome (FCS)
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 31, 2026
Completion date
August 31, 2031
Enrollment
12 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

familial chylomicronemia syndrome